Sponsor:
Ryvu Therapeutics SA
Code:
NCT06268574
Conditions
Acute Myeloid Leukemia (AML)
High-risk Myelodysplastic Syndrome
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
RVU120
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations